Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: A randomized, double-blind phase II study

被引：0
|
作者：
Bang, Yung-Jue
Im, Seock-Ah
Lee, Keun-Wook
Cho, Jae Yong
Song, Eun-Kee
Lee, Kyung Hee
Kim, Yeul Hong
Park, Joon Oh
Chun, Hoo Geun
Zang, Dae Young
Fielding, Anitra
Rowbottom, Jacqui
Kim, Woo Ho
机构：
[1] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Songnam, South Korea
[3] Gangnam Severance Hosp, Seoul, South Korea
[4] Chonbuk Natl Univ, Div Hematol Oncol, Dept Internal Med, Sch Med, Jeonju, South Korea
[5] Yeungnam Univ Hosp, Taegu, South Korea
[6] Korea Univ, Anam Hosp, Seoul, South Korea
[7] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[8] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea
[9] Hallym Univ, Sacred Heart Hosp, Anyang, South Korea
[10] AstraZeneca, Macclesfield, Cheshire, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4013
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
    Bang, Yung-Jue
    Im, Seock-Ah
    Lee, Keun-Wook
    Cho, Jae Yong
    Song, Eun-Kee
    Lee, Kyung Hee
    Kim, Yeul Hong
    Park, Joon Oh
    Chun, Hoo Geun
    Zang, Dae Young
    Fielding, Anitra
    Rowbottom, Jacqui
    Hodgson, Darren
    O'Connor, Mark J.
    Yin, Xiaolu
    Kim, Woo Ho
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (33) : 3858 - +
  • [2] Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
    Davis, Lara E.
    Bolejack, Vanessa
    Ryan, Christopher W.
    Ganjoo, Kristen N.
    Loggers, Elizabeth T.
    Chawla, Sant
    Agulnik, Mark
    Livingston, Michael B.
    Reed, Damon
    Keedy, Vicky
    Rushing, Daniel
    Okuno, Scott
    Reinke, Denise K.
    Riedel, Richard F.
    Attia, Steven
    Mascarenhas, Leo
    Maki, Robert G.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (16) : 1424 - +
  • [3] Apatinib plus paclitaxel versus placebo plus paclitaxel as second-line therapy in patients with gastric cancer with peritoneal carcinomatosis: A double-blind, randomized phase II trial.
    Wang, Fenghua
    Ren, Chao
    Xu, Jianying
    Wang, Zhiqiang
    He, Ming-ming
    Qiu, Miaozhen
    Jin, Ying
    Luo, Huiyan
    Wang, Feng
    Li, Yuhong
    Tan, Qiong
    Zhang, Rong
    Xu, Ruihua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
    Di Leo, Angelo
    Gomez, Henry L.
    Aziz, Zeba
    Zvirbule, Zanete
    Bines, Jose
    Arbushites, Michael C.
    Guerrera, Stephanie F.
    Koehler, Maria
    Oliva, Cristina
    Stein, Steven H.
    Williams, Lisa S.
    Dering, Judy
    Finn, Richard S.
    Press, Michael F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5544 - 5552
  • [5] Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
    Karlan, Beth Y.
    Oza, Amit M.
    Richardson, Gary E.
    Provencher, Diane M.
    Hansen, Vincent L.
    Buck, Martin
    Chambers, Setsuko K.
    Ghatage, Prafull
    Pippitt, Charles H., Jr.
    Brown, John V., III
    Covens, Allan
    Nagarkar, Raj V.
    Davy, Margaret
    Leath, Charles A., III
    Hoa Nguyen
    Stepan, Daniel E.
    Weinreich, David M.
    Tassoudji, Marjan
    Sun, Yu-Nien
    Vergote, Ignace B.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04) : 362 - 371
  • [6] DROLOXIFENE IN POSTMENOPAUSAL PATIENTS WITH METASTATIC BREAST-CANCER - DOUBLE-BLIND RANDOMIZED PHASE-II STUDY
    MARSCHNER, N
    KREIENBERG, R
    BALAS, R
    BRANDTNER, M
    SCHLINGENSIEPEN, R
    SCHUMANN, S
    BUTTNER, S
    STAAB, HJ
    RAUSCHNING, W
    ONKOLOGIE, 1994, 17 : 32 - 39
  • [7] Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer
    Fogelman, David
    Cubillo, Antonio
    Garcia-Alfonso, Pilar
    Limon Miron, Maria Luisa
    Nemunaitis, John
    Flora, Daniel
    Borg, Christophe
    Mineur, Laurent
    Vieitez, Jose M.
    Cohn, Allen
    Saylors, Gene
    Assad, Albert
    Switzky, Julie
    Zhou, Li
    Bendell, Johanna
    CANCER MEDICINE, 2018, 7 (11): : 5382 - 5393
  • [8] Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
    Rugo, Hope S.
    Stopeck, Alison T.
    Joy, Anil A.
    Chan, Stephen
    Verma, Shailendra
    Lluch, Anna
    Liau, Katherine F.
    Kim, Sinil
    Bycott, Paul
    Rosbrook, Brad
    Bair, Angel H.
    Soulieres, Denis
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2459 - 2465
  • [9] A phase II, randomized, double-blind study of the use of rucaparib versus placebo maintenance therapy in metastatic and recurrent endometrial cancer
    Corr, Bradley
    Haggerty, Ashley
    Gysler, Stefan
    Taylor, Sarah
    Behbakht, Kian
    Alldredge, Jill
    Lefkowits, Carolyn
    Brubaker, Lindsay
    Bouts, Catherine
    Babayan, Lisa Marie
    Hopp, Samantha
    Hu, Junxiao
    Guntupalli, Saketh
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S63 - S63
  • [10] A phase II, randomized, double-blind study of the use of rucaparib vs placebo maintenance therapy in metastatic and recurrent endometrial cancer
    Corr, Bradley
    Haggerty, Ashley Ford
    Taylor, Sarah E.
    Gysler, Stefan
    Morgan, Mark Aloysuis
    Behbakht, Kian
    Lefkowits, Carolyn
    Alldredge, Jill
    Brubaker, Lindsay
    Hopp, Samantha
    Guntupalli, Saketh R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345